Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.90 |
| ▸ | MAPT | P10636 | 4/20 | 0.90 |
| ▸ | MEN1 | O00255 | 3/20 | 0.90 |
| ▸ | HTT | P42858 | 2/20 | 0.90 |
| ▸ | RAB9A | P51151 | 1/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | CA12 | O43570 | 1/20 | 0.72 |
| ▸ | CA1 | P00915 | 1/20 | 0.72 |
| ▸ | CA2 | P00918 | 1/20 | 0.72 |
| ▸ | CA9 | Q16790 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | KDR | P35968 | 1/20 | 0.72 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.67 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101230 | 1.00 | KMT2A (0.90) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL4548162 | 0.98 | KMT2A (0.87) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL17609423 | 0.95 | MAPT (1.00) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL30069239 | 0.95 | MAPT (1.00) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL17664317 | 0.95 | KMT2A (0.81) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL10220026 | 0.92 | MTOR (0.80) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL22024980 | 0.92 | KMT2A (0.77) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL17664319 | 0.92 | KMT2A (0.82) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL26416486 | 0.91 | MAPT (0.76) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL22092703 | 0.90 | MAPT (0.79) | KMT2AMAPTMEN1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60264284-A | — | — | None | — | — | JP | disclosed |
| US-20230134821-A1 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20230134821-A1 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-05-04 | — | — | US | disclosed |
| WO-2022255256-A1 | REVERSIBLY THERMOCHROMIC COMPOSITION, WRITING UTENSIL USING SAID REVERSIBLY THERMOCHROMIC COMPOSITION, AND TOY | 三菱ケミカル株式会社 | 2022-12-08 | — | — | WO | disclosed |
| EP-4067340-A1 | DEVELOPER AND THERMOSENSITIVE RECORDING MATERIAL | Mitsubishi Chemical Corporation (JP) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021107037-A1 | DEVELOPER AND THERMOSENSITIVE RECORDING MATERIAL | 三菱ケミカル株式会社 | 2021-06-03 | — | — | WO | disclosed |
| EP-1815860-A2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2007-08-08 | — | — | EP | disclosed |
| EP-1815860-A2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
| US-7119120-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1483257-A1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2004-12-08 | — | — | EP | disclosed |
| EP-1465638-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019113-A1 | Phosphate transport inhibitors | GELTEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003076427-A1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003057225-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
| JP-S60264284-A | THERMAL RECORDING MATERIAL | RICOH CO LTD | 1985-12-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019113-A1 | Phosphate transport inhibitors | SLC34A1, SLC34A2, SLC20A1 | KMT2A 4536/4885MAPT 3148/4885MEN1 2905/4885 |
| US-20070021509-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC20A1 | KMT2A 4634/4885MAPT 3058/4885MEN1 2248/4885 |
| US-20230134821-A1 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | MYC, MYCBP, MAX | KMT2A 699/4885MAPT 297/4885MEN1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.